IL152610A - Non-psychotropic cannabinoids - Google Patents
Non-psychotropic cannabinoidsInfo
- Publication number
- IL152610A IL152610A IL152610A IL15261002A IL152610A IL 152610 A IL152610 A IL 152610A IL 152610 A IL152610 A IL 152610A IL 15261002 A IL15261002 A IL 15261002A IL 152610 A IL152610 A IL 152610A
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- moiety
- group
- compound
- saturated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL152610A IL152610A (en) | 2000-06-22 | 2002-11-03 | Non-psychotropic cannabinoids |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL13694600A IL136946A0 (en) | 2000-06-22 | 2000-06-22 | Novel non-psychotropic cannabinoids |
US22246700P | 2000-07-28 | 2000-07-28 | |
PCT/IL2001/000571 WO2001098289A1 (fr) | 2000-06-22 | 2001-06-22 | Nouveaux cannabinoides non psychotropes |
IL152610A IL152610A (en) | 2000-06-22 | 2002-11-03 | Non-psychotropic cannabinoids |
Publications (1)
Publication Number | Publication Date |
---|---|
IL152610A true IL152610A (en) | 2007-07-04 |
Family
ID=26323959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL152610A IL152610A (en) | 2000-06-22 | 2002-11-03 | Non-psychotropic cannabinoids |
Country Status (12)
Country | Link |
---|---|
US (1) | US6610737B1 (fr) |
EP (1) | EP1299374B1 (fr) |
JP (1) | JP2004501145A (fr) |
KR (1) | KR20030008153A (fr) |
AT (1) | ATE349439T1 (fr) |
AU (1) | AU783522B2 (fr) |
CA (1) | CA2411585A1 (fr) |
DE (1) | DE60125541T2 (fr) |
HU (1) | HUP0301628A3 (fr) |
IL (1) | IL152610A (fr) |
NZ (1) | NZ522349A (fr) |
WO (1) | WO2001098289A1 (fr) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE247097T1 (de) * | 1998-05-04 | 2003-08-15 | Univ Connecticut | Analgetische und immunomodulierende cannabinoiden |
US7589220B2 (en) * | 1998-06-09 | 2009-09-15 | University Of Connecticut | Inhibitors of the anandamide transporter |
US7161016B1 (en) | 1998-11-24 | 2007-01-09 | University Of Connecticut | Cannabimimetic lipid amides as useful medications |
US7276613B1 (en) | 1998-11-24 | 2007-10-02 | University Of Connecticut | Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
US6943266B1 (en) * | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
US7741365B2 (en) * | 1999-10-18 | 2010-06-22 | University Of Connecticut | Peripheral cannabinoid receptor (CB2) selective ligands |
MXPA02005103A (es) | 1999-10-18 | 2003-09-25 | Alexipharma Inc | Ligandos selectivos del receptor de canabinoide (cb2) perifericos. |
US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
US6900236B1 (en) | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
US20020077322A1 (en) * | 2000-12-15 | 2002-06-20 | Ayoub George S. | Protection of neurons against glutamate-induced damage in glaucoma and other conditions |
EP1361876A4 (fr) * | 2001-01-26 | 2004-03-31 | Univ Connecticut | Nouveaux ligands cannabimimetiques |
US7173027B2 (en) | 2001-01-29 | 2007-02-06 | University Of Connecticut | Receptor selective cannabimimetic aminoalkylindoles |
CA2452881C (fr) * | 2001-07-13 | 2012-03-06 | University Of Connecticut | Nouveaux cannabinoides bicycliques et tricycliques |
JP2005510492A (ja) * | 2001-10-26 | 2005-04-21 | ユニバーシティ オブ コネチカット | 新規な種類の効力のあるカンナビミメティックリガンド |
US7029918B2 (en) | 2002-01-25 | 2006-04-18 | Roche Diagnostics Operations, Inc. | Water-soluble derivatives of lipophilic drugs |
GB0202385D0 (en) * | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
US8034843B2 (en) | 2002-02-01 | 2011-10-11 | Gw Pharma Limited | Compositions comprising cannabinoids for treatment of nausea, vomiting, emesis, motion sickness or like conditions |
IL148244A0 (en) | 2002-02-19 | 2002-09-12 | Yissum Res Dev Co | Anti-nausea and anti-vomiting activity of cannabidiol compounds |
IL148736A0 (en) * | 2002-03-18 | 2002-09-12 | Pharmos Corp | Dexanabinol and dexanabinol analogs which regulate inflammation related genes |
CA2496097A1 (fr) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Ceto-cannabinoides possedant des indications therapeutiques |
US20050192341A1 (en) * | 2002-09-05 | 2005-09-01 | Seth Kindler | Non-psychotropic cannabinoids for prevention of cognitive impairment |
AU2003245023A1 (en) * | 2002-09-05 | 2004-03-29 | Pharmos Corporation | Non-psychotropic cannabinoids for prevention of cognitive impairment |
GB2394894B (en) * | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US7169942B2 (en) * | 2003-05-20 | 2007-01-30 | University Of Tennessee Research Foundation | Cannabinoid derivatives, methods of making, and use thereof |
TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
EP1757587A1 (fr) * | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Composés de pyrazoline substituée, leur préparation et leur usage comme médicaments |
EP1743890A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Dérivés 4,5-dihydro-1H-pyrazole, leur, préparation et utilisation comme médicaments. |
US7897589B2 (en) * | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
EP1743892A1 (fr) * | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Composés pyrazoline substitués, leur préparation et utilisation comme médicaments |
EP2578561A1 (fr) | 2005-09-29 | 2013-04-10 | Albany Molecular Research, Inc. | Procédés pour la production de dérivés de cannabidiol et leurs intermédiaires |
CN100516067C (zh) * | 2006-01-10 | 2009-07-22 | 上海恒瑞医药有限公司 | 具有抗肿瘤活性的紫杉酚衍生物 |
EP2089383B1 (fr) | 2006-11-09 | 2015-09-16 | Probiodrug AG | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
EP2151234A1 (fr) * | 2008-07-28 | 2010-02-10 | Laboratorios Del. Dr. Esteve, S.A. | Formulation pharmaceutique comprenant un composé récepteur CB1 dans une solution solide et/ou une dispersion solide |
GB0915877D0 (en) | 2009-09-10 | 2009-10-14 | E Therapeutics Plc | Cancer cell apoptosis |
PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (fr) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Nouveaux inhibiteurs |
GB201207305D0 (en) | 2012-04-26 | 2012-06-13 | E Therapeutics Plc | Therapy |
WO2015025312A1 (fr) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions combinant une libération immédiate et une libération prolongée de cannabinoïdes, leurs méthodes de fabrication et d'utilisation |
US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
WO2019159168A1 (fr) * | 2018-02-13 | 2019-08-22 | Beetlebung Pharma Ltd. | Dérivés et conjugués de cannabinoïdes et leurs utilisations |
CN115286606B (zh) * | 2022-09-09 | 2023-09-29 | 中国科学院昆明植物研究所 | 一种天麻黄酮类化合物及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521215A (en) * | 1989-11-07 | 1996-05-28 | Ramot University Authority For Applied Research And Industrial Development Ltd. | NMDA-blocking pharmaceuticals |
US6096740A (en) * | 1990-11-06 | 2000-08-01 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions |
US5538993A (en) * | 1991-09-12 | 1996-07-23 | Yissum Research Development Company | Certain tetrahydrocannabinol-7-oic acid derivatives |
US5635530A (en) * | 1991-09-12 | 1997-06-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them |
US5440052A (en) * | 1993-08-06 | 1995-08-08 | University Of Connecticut | Compositions useful as a cannabinoid receptor probe |
IL115245A (en) * | 1995-09-11 | 2002-12-01 | Yissum Res Dev Co | Tumor necrosis factor inhibiting pharmaceuticals |
DE19706903A1 (de) * | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
US6162829A (en) * | 1997-10-17 | 2000-12-19 | Atlantic Pharmaceuticals, Inc. | (3R,4R)-Δ8 -tetrahydrocannabinol-11-oic acids useful as antiinflammatory agents and analgesics |
WO1999057107A2 (fr) * | 1998-05-04 | 1999-11-11 | The University Of Connecticut | Cannabinoides specifiques au recepteur cb2 |
-
2001
- 2001-06-22 CA CA002411585A patent/CA2411585A1/fr not_active Abandoned
- 2001-06-22 EP EP01945578A patent/EP1299374B1/fr not_active Expired - Lifetime
- 2001-06-22 NZ NZ522349A patent/NZ522349A/en unknown
- 2001-06-22 KR KR1020027016931A patent/KR20030008153A/ko not_active Application Discontinuation
- 2001-06-22 JP JP2002504245A patent/JP2004501145A/ja active Pending
- 2001-06-22 AU AU67789/01A patent/AU783522B2/en not_active Ceased
- 2001-06-22 HU HU0301628A patent/HUP0301628A3/hu unknown
- 2001-06-22 WO PCT/IL2001/000571 patent/WO2001098289A1/fr active IP Right Grant
- 2001-06-22 DE DE60125541T patent/DE60125541T2/de not_active Expired - Fee Related
- 2001-06-22 AT AT01945578T patent/ATE349439T1/de not_active IP Right Cessation
-
2002
- 2002-11-03 IL IL152610A patent/IL152610A/en not_active IP Right Cessation
- 2002-11-26 US US10/304,074 patent/US6610737B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU783522B2 (en) | 2005-11-03 |
EP1299374A4 (fr) | 2004-09-22 |
NZ522349A (en) | 2004-06-25 |
DE60125541T2 (de) | 2007-10-11 |
ATE349439T1 (de) | 2007-01-15 |
CA2411585A1 (fr) | 2001-12-27 |
HUP0301628A3 (en) | 2007-05-29 |
EP1299374A1 (fr) | 2003-04-09 |
DE60125541D1 (de) | 2007-02-08 |
EP1299374B1 (fr) | 2006-12-27 |
KR20030008153A (ko) | 2003-01-24 |
US6610737B1 (en) | 2003-08-26 |
WO2001098289A1 (fr) | 2001-12-27 |
AU6778901A (en) | 2002-01-02 |
JP2004501145A (ja) | 2004-01-15 |
HUP0301628A2 (hu) | 2003-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU783522B2 (en) | Novel non-psychotropic cannabinoids | |
US5284867A (en) | NMDA-blocking pharmaceutical compositions | |
DE69833010T2 (de) | Cannabinol-11-säurederivate als entzündungshemmer und analgetika | |
CA2599352A1 (fr) | Nouveaux inhibiteurs de la lipoxygenase | |
US20070213369A1 (en) | Novel non-psychotropic cannabinoids | |
JP2001520629A (ja) | ホスホジエステラーゼ▲iv▼を阻害する化合物および方法 | |
EP1060160A2 (fr) | Analogues de lavendustine a disubstitues et compositions pharmaceutiques contenant ces analogues | |
JPS6150977A (ja) | 新規な縮合ベンズ(チオ)アミド、それらの製造方法およびそれらを有効成分として含有する薬剤 | |
CA2029419C (fr) | Compositions pharmaceutiques bloquant le nmda | |
EP1785417A2 (fr) | Cannabinoïdes non-psychotropes originaux | |
KR100395308B1 (ko) | 페룰릭산 이합체 및 그의 약학적 허용 염, 그 제조방법 및치매 치료를 위한 그의 용도 | |
JPS63258854A (ja) | カルボキシスチレン誘導体およびそれを有効成分とする薬剤 | |
KR940011151B1 (ko) | 시클로알킬 우레아 화합물 | |
EP1118324A1 (fr) | Analgésique, contenant un dérivé d'acide cyclobutane dicarboxylique | |
US20050054720A1 (en) | Saururus cernuus compounds that inhibit cellular responses to hypoxia | |
CN113304129B (zh) | 单烯酮类单羰基姜黄素类似物在制备抗氧化药物的应用 | |
RU2799454C2 (ru) | Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение | |
CA2173305A1 (fr) | Derive de la pyrazolidine, capteur de radicaux, inhibiteur d'infarctus et d'oedemes cerebraux | |
JP3857428B2 (ja) | 抗真菌剤 | |
JPH0662584B2 (ja) | 新規ヒダントイン誘導体及び該化合物を含有する脂質低下剤 | |
KR20020072815A (ko) | 신규한 패혈증 치료제 | |
JPS63267717A (ja) | カルシウムホメオスタシスの緩和に対するマノアリドおよびその誘導体の利用 | |
KR19990086659A (ko) | 신규한 패혈증 치료제 | |
JPH02247122A (ja) | 抗炎症剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM9K | Patent not in force due to non-payment of renewal fees |